Canada Markets closed

Mind Medicine (MindMed) Inc. (MMED.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
1.0000+0.0900 (+9.89%)
At close: 03:59PM EDT
Full screen
Previous Close0.9100
Open0.9100
Bid0.9200 x N/A
Ask1.0000 x N/A
Day's Range0.9100 - 1.0000
52 Week Range0.9100 - 4.9100
Volume235,434
Avg. Volume344,161
Market Cap421.202M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.2350
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal

    Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers.

  • CNW Group

    MindMed Announces At-The-Market Offering

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022, was declared effective by the U.S. Securities and Exchange Commission, which includes a prospectus for an at-the-market equity offering under which the Company may offer and sell its Subordinate Voting Shares or common shares re-designated f

  • CNW Group

    MindMed Reports First Quarter 2022 Financial Results and Business Highlights

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2022.